When Survival Improves But Quality of Life Does Not: A Model-Based Meta-Analysis of Immune Checkpoint Inhibitors
Conventional analyses comparing QoL at a single time point may obscure meaningful patient-reported benefits. By capturing longitudinal QoL trajectories across trials, MBMA reveals how patient experience evolves alongside survival outcomes and supports improved interpretation and utilization of QoL data in treatment evaluation.
Authors
- Adam C. Palmer (ORCID: https://orcid.org/0000-0001-5028-7028)
- Shiwon Chang
- Malidi Ahamadi (ORCID: https://orcid.org/0000-0002-9733-5709)
- Matthew LeBlanc
- Jiawei Zhou
- Kayden Tang
- Yimeng Sun
Institutions
- University of North Carolina at Chapel Hill (US)
- East Central University (US)
- Morristown Medical Center (US)
Publication Details
- Journal
- medRxiv
- Published
- 2026-03-05
- DOI
- https://doi.org/10.64898/2026.03.04.26347610
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Sanofi
- National Institutes of Health
- National Cancer Institute